Fair Money & Economic Opportunity

Atara Biotherapeutics is a biopharmaceutical company focused on developing T-cell immunotherapies.

Its core business does not involve lending, insuring, moving, or storing money for consumers. Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to the company's operations.

Fair Pay & Worker Respect

Atara Biotherapeutics has an overall employee rating of 3.6 out of 5 stars, based on 111 or 112 reviews.

63% of employees would recommend working at the company, and 77% approve of the CEO. The business outlook is rated positively by 35% of employees. The compensation and benefits rating is 3.4 out of 5 stars, which improved by 4% over the last 12 months, while work/life balance is rated 3.0 out of 5 stars. The company has undergone significant workforce reductions, including 20% in 2022, 30% in 2023, 25% in 2024, and 50% in March 2025, which is expected to leave 23 employees by August 2025. These layoffs are estimated to cost $1.4 million in severance and related benefits.

Kind to Animals

Atara Biotherapeutics conducts animal studies as part of the preclinical testing required by the FDA for product development.

These studies must comply with federal regulations, Good Laboratory Practices (GLPs), and applicable requirements for the humane use of laboratory animals. The company uses between 50,000 and 100,000 animals annually in its testing protocols, with no transparent reduction targets mentioned.

No War, No Weapons

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing T-cell immunotherapies. Its revenue in 2021 was $20.3 million, primarily from agreements with Bayer,

and in 2023, commercialization revenue was $7.9 million, mainly from sales of Ebvallo in the EU to Pierre Fabre. The company's core business activities, including research and development for therapies and manufacturing agreements, do not involve arms manufacturing, defense contracts, or any military-related activities. No evidence was found regarding dual-use technologies, sales to embargoed regimes, or any other metrics related to military or conflict-related operations.

Planet-Friendly Business

No specific quantitative data or concrete actions related to planet-friendly business practices, such as carbon emissions, renewable energy use, water consumption, waste diversion rates, or environmental certifications, were found in the provided articles for Atara Biotherapeutics, Inc.

The articles primarily focus on general ESG risk assessments and overall impact scores without detailing specific environmental metrics or initiatives.

Respect for Cultures & Communities

Atara Biotherapeutics, a biopharmaceutical company, has no formal partnerships with indigenous or local community groups, which aligns with a business model where such partnerships are not typically applicable.

The company's partnerships are primarily with commercial, research, and manufacturing entities.

Safe & Smart Tech

Atara Biotherapeutics experienced a network security incident on November 2, 2023, involving unauthorized access to internal systems.

This incident, discovered on June 10, 2024, exposed sensitive personal information including names, social security numbers, dates of birth, addresses, government IDs, medical information, financial information, and digital signatures. Notification letters were sent to affected individuals and various state and federal agencies, including the U.S. Dept. of Health & Human Services and the U.S. Securities & Exchange Commission, by August 16, 2024. This represents one incident of unauthorized data use within the past year. While the company includes extensive representations and warranties in stock sales agreements regarding compliance with regulations such as HIPAA, CCPA, and GDPR, the occurrence of this data breach indicates a gap in actual compliance or preventative measures.

Zero Waste & Sustainable Products

Atara Biotherapeutics implements waste stream segregation for landfill and recyclables at its facilities, which counts as one small-scale waste reduction initiative.

The company's internal assessment identifies 'Waste' as a category causing negative environmental impact. For hazardous waste, the company states it believes its safety procedures for handling and disposing of materials comply with state and federal regulations, and the manufacturer is responsible for the generation, collection, storage, handling, transportation, movement, and release of hazardous materials and waste. However, a third-party manufacturing facility for tab-cel had inadequately addressed Good Manufacturing Practices (GMP) compliance issues, leading to a Complete Response Letter from the FDA and a clinical hold on Atara's active Investigational New Drug (IND) applications. Atara's Supplier Code of Conduct mandates that suppliers perform due diligence on the source of critical raw materials to promote legal and sustainable sourcing, and manufacturers must supply materials in accordance with approved raw material specifications.